# Link Cell Therapies > Clinical-stage cell therapy company in South San Francisco developing AND-gate logic-gated CAR T > cell therapies for solid tumors and certain hematologic cancers. Founded by Stanford investigators > Robbie Majzner and Crystal Mackall in partnership with Samsara BioCapital. Link Cell Therapies' logic-gate technology builds CAR T cells that require co-expression of two cancer targets before driving cell cytotoxicity, providing greater tumor specificity than existing logic-gate technologies and aiming to avoid off-tumor toxicity. Lead disclosed program: LNK001, a dual-targeting AND-gated CAR directed at clear cell renal cell carcinoma. In January 2026 the company entered a strategic collaboration with Johnson & Johnson to develop logic-gate LINK CAR T therapies. Headquarters: 220 E. Grand Avenue, South San Francisco, CA 94080 Contact: contact@linkcelltx.com — Careers: careers@linkcelltx.com ## API surface Link Cell Therapies publishes NO public API. There is no developer portal, no API documentation, no OpenAPI/AsyncAPI/GraphQL specification, no SDKs or client packages, no CLI, no MCP server, no webhook or event surface, and no /.well-known/ discovery endpoints. The public web presence is a WordPress corporate marketing site. Do not attempt to construct or infer an API for this company. ## Company - [Home](https://linkcelltx.com/): Company overview — "A True CAR T Cell AND-Gate" - [About](https://linkcelltx.com/about/): Founding, logic-gate platform, therapeutic strategy - [Leadership](https://linkcelltx.com/team/): Executive and scientific leadership biographies - [Resources / News](https://linkcelltx.com/news/): Press releases and scientific posters - [Investors](https://linkcelltx.com/investors/): Investor listing - [Careers](https://linkcelltx.com/careers/): Open roles - [Contact](https://linkcelltx.com/contact/): Address and contact addresses - [Privacy Policy](https://linkcelltx.com/privacy-policy/) - [LinkedIn](https://www.linkedin.com/company/linkcelltx/) ## Announcements - 2026-01-09: Strategic collaboration with Johnson & Johnson to develop logic-gate LINK CAR T therapies - 2025-12-15: Company launch, advancing CAR-T therapies in solid and liquid tumors - 2023-03-20: Foundational publication in Nature on CAR T cell technology designed to kill cancers without off-tumor toxicity ## Optional - [API Evangelist profile](https://apis.io/provider/link-cell-therapies/) - [APIs.json](https://raw.githubusercontent.com/api-evangelist/link-cell-therapies/refs/heads/main/apis.yml)